[Pilot study of an alternative CYVADIC + CBDCA protocol for adult soft tissue sarcoma as adjuvant chemotherapy].
An alternative CYVADIC + CBDCA protocol was tried as a postoperative adjuvant chemotherapy for patients with adult soft tissue sarcoma. The regimen for CYVADIC was day 1: VCR: 1.5 mg/m2 (day 1), doxorubicin: 50 mg/m2 (day 1), DTIC: 250 mg/m2 (day 1-2), and cyclophosphamide: 500 mg/m2 (day 2), and that for CBDCA was 400 mg/m2. CYVADIC and CBDCA were administered alternatively for 3 cycles each. From July 1995 to December 1997, 80 patients with soft tissue sarcoma underwent surgery in our hospital. This protocol was used in 8 of these cases of high grade adult soft tissue sarcoma. Round cell sarcoma was excluded from this study. The 5-year disease free survival rate was 60% and the overall survival rate was 70%. Three cases showed lung metastases. Two patients died of disease and one patient survives free from disease after removal of the lung metastases. No patients showed severe toxicity. We conclude that this protocol merits further evaluation.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012509:Sarcoma / Q000188:drug therapy* / Q000601:surgery; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000601:surgery; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin